

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Michael Paul Brown, et al.	Examiner:	K. T. Hiriyanna
Serial No.:	10/569,157	Art Unit:	1633
Filed:	October 13, 2006	Docket:	19610
For:	POXVIRUS VECTOR ENCODING PROSTATE SPECIFIC ANTIGENS FOR TREATMENT OF PROSTATE CANCER	Dated:	May 15, 2009

Confirmation No.: 7808

Commissioner for Patents
Alexandria, VA 22313-1450

RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143


Sir:

In response to the Office Action dated March 26, 2009, setting forth a requirement for restriction, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, Applicants provisionally elect, with traverse, the subject matter of Group I, claims 1-19 and 21, drawn to a genetic vaccine construct comprising an avipoxvirus that expresses a prostate specific polypeptide or a derivative thereof and optionally a sequence of nucleotides encoding an immunostimulatory peptide, and to a hybridization probe. Further, in connection with the requirement for species election, Applicants provisionally elect IL-2.

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website on the date shown below.

Dated: May 15, 2009


Xiaochun Zhu